AGÕæÈ˹ٷ½

Q2-25 results: NeoGenomics (NEO) generated net revenue of $181.3 million, up 10.2% YoY; client-direct billing remained the largest channel (72% of sales). Gross profit increased 6.6% to $77.3 million but gross margin fell 150 bp to 42.6% as cost-of-revenue growth out-paced pricing.

Expenses & earnings: Operating costs rose 32% to $124.9 million, driven by $20.0 million in impairments (InVisionFirst-Lung wind-down & planned Trapelo divestiture) plus higher G&A, R&D and sales spend. Operating loss widened to $47.6 million (-$21.9 million LY); GAAP EPS was â€�$0.35 vs â€�$0.15. 1H-25 net loss reached $71.0 million.

Liquidity & leverage: Operating cash burn improved to â€�$5.0 million (1H-24 â€�$12.0 million). Cash & equivalents shrank to $154.7 million from $367.0 million after repaying the $201.3 million 1.25% 2025 converts. Balance-sheet debt now consists mainly of the $341.1 million 0.25% 2028 convertible notes; net debt rose to $186.4 million. Current ratio eased to 3.9x (FY-24 3.0x).

Strategic/other: Closed $8.3 million Pathline acquisition (adds $4.7 million 1H revenue) and classified Trapelo Health as held-for-sale. Goodwill stands at $524.1 million; intangible assets $301.8 million post-write-downs. An $11.2 million reserve remains for an ongoing OIG/DOJ investigation; patent litigation with Natera and shareholder suits remain unresolved.

MTB Form 4 (filed 07/24/25): Sr. EVP Peter D’Arcy reports open-market sales of common shares.

• On 07/22/25, D’Arcy sold 1,937 shares at a $197.17 weighted-average price (range $196.62-$197.60) and 524 shares at $197.82 (range $197.61-$198.05), disposing of 2,461 shares in total.
• Estimated gross proceeds are roughly $0.49 million.
• Direct ownership declined from 11,780 to 9,319 shares, a ~21% reduction.
• He also holds 327 phantom stock units in a Supplemental 401(k) Plan; these are cash-settled and unchanged.

No shares were acquired, no options exercised, and the filing does not reference a Rule 10b5-1 plan. While executives may sell for personal reasons, such disposals can be viewed by investors as a modestly negative sentiment signal absent further context.

Transcat, Inc. (Nasdaq: TRNS) filed an 8-K on 16-Jul-2025 reporting a board change under Item 5.02. Director Charles P. Hadeed notified the Company of his intent to retire effective 1-Aug-2025 after 23 years of service, including 18 years as a board member. The filing states the resignation is not related to any disagreement concerning the Company’s operations, policies or practices. No other executive changes, strategic actions or financial data were disclosed.

JPMorgan Chase Financial Company LLC is marketing a three-year structured note titled 3y RAY/SX5E Basket Dual Directional Trigger PLUS. The note is linked to a basket comprising the Russell 3000® Index (40% weight) and the EURO STOXX 50® Index (60% weight). Key commercial terms are as follows:

• Upside participation: 200% leveraged exposure to basket gains, subject to a maximum payment of at least $1,325.50 (132.55% of principal).
• Dual-directional feature: If the basket finishes flat or declines by â‰�15%, investors receive a positive return equal to the absolute basket move (e.g., â€�10% basket change âž� +10% payout), capped at $1,150.
• Trigger level: 85% of the initial basket value. A close below this level on the valuation date results in loss of principal in line with basket performance, up to total loss.
• Maturity & dates: Pricing expected 1 Jul 2025; valuation 3 Jul 2028; maturity 7 Jul 2028.
• Issue price / estimated value: $1,000 per note; estimated value on pricing date will not be less than $920.
• Credit exposure: Payments depend on the senior unsecured obligations of JPMorgan Financial (issuer) and JPMorgan Chase & Co. (guarantor).

The note provides enhanced upside (2× leverage) and limited downside buffer (15%) but introduces several risks, including capped gains, full downside beyond the trigger, secondary-market illiquidity, and potential issuer credit deterioration. The product is intended for investors with a moderately bullish, range-bound, or slightly bearish three-year view on the basket who can tolerate the possibility of significant capital loss.

On 18 June 2025, Bandwidth Inc. (BAND) filed a Form S-8 with the SEC to register an additional 4,500,000 shares of Class A common stock for issuance under its Third Amended and Restated 2017 Incentive Award Plan. The filing is made pursuant to General Instruction E, incorporating four prior S-8 registrations that together covered more than 15 million shares under various equity plans. Standard exhibits—such as the full plan document, legal opinion from Latham & Watkins, and the auditor’s consent from Ernst & Young—are included. The document contains no new financial results, transactions, or strategic updates; it is strictly an administrative move to ensure sufficient share capacity for future equity-based compensation.